{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Liver&page=9", "query": { "condition": "Cancer of the Liver", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1423, "total_pages": 143, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Liver&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Liver&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T12:28:31.557Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01625351", "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Gastrointestinal Tumor", "Germ Cell Tumor", "Hepatic Tumor", "Lymphoma", "Wilms Tumor", "Rhabdoid Tumor", "Clear Cell Carcinoma", "Renal Cell Carcinoma", "Melanoma", "Neuroblastoma", "Rhabdomyosarcoma", "Non-rhabdomyosarcoma" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "stem cells", "type": "BIOLOGICAL" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 23, "start_date": "2012-08-20", "completion_date": "2020-02-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625351" }, { "nct_id": "NCT00108953", "title": "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin/Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2005-04", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108953" }, { "nct_id": "NCT00692770", "title": "Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Nexavar (Sorafenib, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1114, "start_date": "2008-08-15", "completion_date": "2014-11-28", "has_results": true, "last_update_posted_date": "2018-08-08", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00692770" }, { "nct_id": "NCT07343960", "title": "A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Moderate Hepatic Impairment" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2026-01-06", "completion_date": "2026-11-11", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 2, "location_summary": "Rialto, California • San Antonio, Texas", "locations": [ { "city": "Rialto", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07343960" }, { "nct_id": "NCT05602194", "title": "Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like", "Lymphoblastic Lymphoma", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 440, "start_date": "2023-08-24", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 225, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602194" }, { "nct_id": "NCT00607828", "title": "Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "stereotactic body radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2007-11-16", "completion_date": "2017-02-15", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607828" }, { "nct_id": "NCT06915753", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Solid Tumors", "Solid Tumor, Adult", "FGFR Gene Amplification", "FGFR Gene Alterations", "Advanced Solid Tumors", "FGFR4 Gene Mutation", "FGFR4 Gene Fusions", "FGF19 Gene Amplification", "FGF19 Gene Overexpression", "Locally Advanced Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "TYRA-430", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-04-24", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915753" }, { "nct_id": "NCT00589030", "title": "Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "brachytherapy", "type": "RADIATION" }, { "name": "yttrium Y 90 glass microspheres", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2007-04", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589030" }, { "nct_id": "NCT03482102", "title": "Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-05-14", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03482102" }, { "nct_id": "NCT06921785", "title": "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1220, "start_date": "2025-05-06", "completion_date": "2030-03-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-11T12:28:31.557Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06921785" } ] }